Welcome to Demei Chemical Technology Co., Ltd
📞 +86-0536-2205782 📧 arron.seagulls@gmail.com
Language: English | Japanese | Russian

1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane

CAS No.: 28523-86-6

  • Molecular Formula: C₄H₃F₇O
  • Molecular Weight: 200.05 g/mol

Chemical type

  • Inhaled volatile anesthetic (halogenated ether)
[1]
  • Halogenated inhalation anesthetic
[2]

Key properties

  • Low blood-gas solubility for rapid induction and emergence
  • Provides hypnosis and amnesia
[1]
  • Used for general anesthesia in humans and animals
  • Male reproductive toxicity in rats: decreases in testicular sperm count, LH, FSH, testosterone; apoptosis of Sertoli cells and primary spermatocytes
  • Oxidative stress mechanism observed at high doses (increased malondialdehyde, decreased superoxide dismutase)
  • Neurological effects: affects hippocampal theta oscillations and memory in animal studies
[2]
  • Anesthesia maintenance (1-1.5% inhalation)
  • Maintains BIS 40-60 and stable hemodynamics during surgery
[1]
  • General anesthesia in hospital and veterinary settings
  • Research use in animal facilities
[2]

Classification by use

  • Inhaled general anesthetics

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

  1. [Cite:1] Lidocaine mitigates cognitive decline in elderly patients after video-assisted thoracoscopic surgery: A double-blind randomized controlled clinical trial, Brain Disorders, Volume 21, March 2026, 100308
  2. [Cite:2] A health-based recommended occupational exposure limit for isoflurane and sevoflurane using experimental animal data based on a systematic review and dose-response analysis, Environmental Toxicology and Pharmacology, Volume 121, January 2026, 104916